Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions

Biochemical and Biophysical Research Communications

Volumn 392, Issue 3, 2010, Pages 460-466

  Momose, Isao ^a   Ohba, Shun ichi ^a   Tatsuda, Daisuke ^a   Kawada, Manabu ^a   Masuda, Tohru ^a   Tsujiuchi, Go ^b   Yamori, Takao ^c   Esumi, Hiroyasu ^d   Ikeda, Daishiro ^a  

^a Numazu Bio Medical Research Institute   (Japan)

^b MEIJI SEIKA KAISHA LTD   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Efrapeptin F; Glucose; Glucose deprivation; Mitochondria; Mitochondrial inhibitors; Nutrient deprivation

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; ATPENIN A5; CISPLATIN; EFRAPEPTIN F; GLUCOSE; OXIDOREDUCTASE INHIBITOR; ROTENONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL HYPOXIA; CELL LEVEL; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUTRITIONAL DEFICIENCY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SERUM;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME INHIBITORS; GLUCOSE; HUMANS; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; PANCREATIC NEOPLASMS; PEPTIDES;

EID: 76349101134     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.01.050     Document Type: Article

References (29)

1. Vaupel P., Kallinowski F., and Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49 (1989) 6449-6465
2. Brown J.M., and Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58 (1998) 1408-1416
3. Izuishi K., Kato K., Ogura T., Kinoshita T., and Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res. 60 (2000) 6201-6207
4. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19 (2000) 5574-5581
5. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4 (2004) 505-518
6. Kunimoto S., Lu J., Esumi H., Yamazaki Y., Kinoshita N., Honma Y., Hamada M., Ohsono M., Ishizuka M., and Takeuchi T. Kigamicins, novel antitumor antibiotics. I. Taxonomy, isolation, physico-chemical properties and biological activities. J. Antibiot. 56 (2003) 1004-1011
7. Kunimoto S., Someno T., Yamazaki Y., Lu J., Esumi H., and Naganawa H. Kigamicins, novel antitumor antibiotics. II. Structure determination. J. Antibiot. 56 (2003) 1007-1012
8. Lu J., Kunimoto S., Yamazaki Y., Kaminishi M., Esumi H., and Esumi H. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. Cancer Sci. 95 (2004) 547-552
9. Momose I., Kunimoto S., Osono M., and Ikeda D. Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells. Biochem. Biophys. Res. Commun. 380 (2009) 171-176
10. Denko N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 8 (2008) 705-723
11. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 4 (2004) 891-899
12. Kroemer G., and Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13 (2008) 472-482
13. Hirayama A., Kami K., Sugimoto M., Sugawara M., Toki N., Onozuka H., Kinoshita T., Saito N., Ochiai A., Tomita M., Esumi H., and Soga T. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 69 (2009) 4918-4925
14. Levine B., and Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 6 (2004) 463-477
15. Gupta S., Krasnoff B.S., Roberts W.D., Renwick A.A.J., Brinen S.L., and Clardy J. Structures of the efrapeptins: potent inhibitors of mitochondrial ATPase from the fungus Tolypocladium niveum. J. Am. Chem. Soc. 113 (1991) 707-709
16. Gupta S., Krasnoff B.S., Roberts W.D., Renwick A.A.J., Brinen S.L., and Clardy J. Structure of efrapeptins from the fungus Tolypocladium niveum: peptide inhibitors of mitochondrial ATPase. J. Org. Chem. 57 (1992) 2306-2313
17. Cross R.L., and Kohlbrenner W.E. The mode of inhibition of oxidative phosphorylation by efrapeptin (A23871). Evidence for an alternating site mechanism for ATP synthesis. J. Biol. Chem. 253 (1978) 4865-4873
18. Kawada M., Momose I., Someno T., Tsujiuchi G., and Ikeda D. New atpenins, NBRI23477A and B, inhibit the growth of human prostate cancer cells. J. Antibiot. 62 (2009) 243-246
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
20. Ueki M., Machida K., and Takeuchi M. Antifungal inhibitors of mitochondrial respiration: discovery and prospects for development. Curr. Opin. Investig. Drugs 2 (2000) 387-398
21. Orme-Johnson N. Direct and indirect inhibitors of mitochondrial ATP synthesis. Methods Cell Biol. 80 (2007) 813-826
22. Miyadera H., Shiomi K., Ui H., Yamaguchi Y., Masuma R., Tomoda H., Miyoshi H., Osanai A., Kita K., and Omura S. Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase). Proc. Natl. Acad. Sci. USA 100 (2003) 473-477
23. Dan S., Tsunoda T., Kitahara O., Yanagawa R., Zembutsu H., Katagiri T., Yamazaki K., Nakamura Y., and Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62 (2002) 1139-1147
24. Yamori T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother. Pharmacol. 52 Suppl. 1 (2003) S74-S79
25. Yamori T., Matsunaga A., Sato S., Yamazaki K., Komi A., Ishizu K., Mita I., Edatsugi H., Matsuba Y., Takezawa K., Nakanishi O., Kohno H., Nakajima Y., Komatsu H., Andoh T., and Tsuruo T. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res. 59 (1999) 4042-4049
26. Dang C.V., and Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 24 (1999) 68-72
27. Southerland R.M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240 (1988) 178-184
28. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3 (1997) 177-182
29. Warburg O. On respiratory impairment in cancer cells. Science 124 (1956) 269-270